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ABSTRACT 
The protein monomer of bacterial flagella, FliC, is known to stimulate human innate 
immunity through activation of Toll-like receptor five. Linking native Salmonella FliC with 
various antigens has demonstrated an increased immune response as compared to single antigen 
presentation. To drastically reduce production time and allow for a more cost effective 
recombinant vaccine adjuvant, a synthetic construct was created that enables genetic linkage of 
FliC to other known antigens. The construct contains the necessary components for immune 
system stimulation while the non-essential regions were replaced with commonly used restriction 
enzyme recognition sites to aid in ligation with other antigens and cloning into various 
expression vectors and hosts. After synthesis in the inducible expression vector pJ404, the 
construct was transformed into competent BL21 E. coli and expression was confirmed through 
SDS-PAGE, Western blot, and MALDI MS/MS. The cells were adapted to fermentation media 
and re-screened for expression, and upon confirmation a 20-liter fermentation was conducted. 
The resulting samples were analyzed for expression within the insoluble and soluble cellular 
fractions to further optimize fermentation conditions. Once purified, this synthetic FliC will 
serve as a platform technology for the standardized co-expression of the TRL5 activator with a 
variety of antigens in both prokaryotic and eukaryotic systems. 
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1 INTRODUCTION  
1.1 Vaccines and The Human Immune Response 
 The global use of safe and effective vaccines is needed to ward against potentially harmful, 
infectious diseases (Curtiss, 2002). According to the World Health Organization (WHO), 1.5 
million children under the age of 5 died from vaccine-preventable diseases (VPDs) in 2012 
(Global Immunization Data, 2014). Closer to home, the September 11, 2001 attacks on the 
United States have increased governmental awareness and funding for defense programs against 
bioterrorism involving both troops and civilians (Cohen and Marshall, 2001). With such foci, 
diseases like measles, tetanus, yellow fever, and pertussis can all currently be avoided by 
following proper vaccination protocols (CDC, 2006). The American Academy of Microbiology 
(2005) has identified a variety of agents that pose a significant health threat for which there are 
currently no licensed vaccines (Table 1). To significantly reduce the number of individuals 
affected by preventable diseases and work toward disease eradication and terrorism protection, 
vaccine development must be at the forefront of research and funding endeavors. To this end, 
microbial expression systems can be designed to produce high yields of immunogenic vaccine 
components in a short amount of time, reducing the overall process time and cost. 
 Vaccines simulate initial pathogen exposure through the delivery of known antigenic 
cellular components, often with the addition of adjuvants to help surmount an immune response. 
Current adjuvants include aluminum salts, oil-in-water emulsions, virosomes, and phospholipids 
and serve to enhance the efficacy of weak antigens or to decrease the dosage required to activate 
the immune system  (Reed et al., 2013). Upon antigen recognition, the body begins a complex 
signaling cascade to rid the bacteria, virus, toxins, or other non-self molecule through the innate 
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and adaptive immune systems.  The specialized adaptive immune system consists primarily of B 
and T cells that, upon antigen-recognition and subsequent activation, recruit the production of 
specific antibodies to clear the invader in a matter of days.   
  
Table 1: Infectious agents that pose significant human health problems 
 with no licensed vaccines available (Vaccine Development: Current Status and 
Future Needs. A report from the American Academy of Microbiology, 2005)  
 
                        
  
                                                                                                                                               
 The innate immune system detects non-self molecules through the activation of Toll-like 
receptors (TLRs) within hours after initial exposure, leading to an inflammatory response and 
Sexually Transmitted 
Agents 
Human Immunodeficiency Virus (HIV) 
Human Papilloma Virus (HPV) 
Herpes Simplex Virus (HSV) 
Chlamydia trachomatis  
Neisseria gonorrhoeae 
Treponema pallidum 
Respiratory Agents 
Respiratory Syncytial Virus (RSV) 
Parainfluenza Virus 
Human Metapneumovirus (HMPV) 
Group A Streptococci 
Chlamydia pneumoniae 
Meningococcus B 
Enteric Agents 
Salmonella species 
Shigella species 
Escherichia coli (ETEC, EHEC, EPEC) 
Helicobacter pylori 
Noroviruses 
Vectorborne Agents 
Plasmodium falciparum 
Dengue Fever Virus 
Hantaviruses 
Borrelia burgdorferi 
Schistosoma species 
Leishmania species 
Hookworm 
Nosocomial Agents 
Staphylococcus aureus 
Pseudomonas species 
Enterococcus species 
Gram negative enteric bacteria 
Candida species 
Other Agents 
Hepatitis C, E viruses 
Cytomegalovirus 
Group B Streptococcus 
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activation of adaptive immune cells. TLRs consist of a leucine-rich extracellular domain and a 
highly conserved intra-cytoplasmic domain (Takeda et al., 2003) and are expressed on a variety 
of lymphocytes, including dendritic and natural killer (NK) cells (Figure 1, Kaisho and Akira, 
2002). Dendritic cells at the site of infection utilize TLRs to recognize non-self molecules, 
causing these cells to migrate to nearby lymph nodes where they play a critical role in antigen 
presentation and T-cell activation. Concurrently, activation of TLRs on NK cells leads to the 
release of inflammatory cytokines and antimicrobial molecules. Through this interworking, the 
innate immune system not only provides the first line of defense against invading 
microorganisms, but it also recruits a more long-lasting, effective immunity.  
 
 
Figure 1: Role of TLRs in Innate Immunity 
Toll-like receptors are found on dendritic cells and play a crucial role in  
antigen presentation and T-cell activation. 
 
 Mammals have ten highly conserved TLRs, each recognizing a specific pathogen-
associated molecular pattern (PAMP) (Janeway, 1989). These PAMPs are evolutionarily stable 
and critical to the organism’s survival. For example, TLR3 recognizes double stranded RNA, 
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like that of retroviruses, while TLR4 recognizes the lipopolysaccharide of Gram-negative 
bacteria (McInturff et al., 2006). This research, however, specifically focuses on the activation of 
TLR5 by FliC, the major structural component of Salmonella flagellin (Hayashi et al., 2001).  
1.2 FliC Structure and TLR5 Recognition 
 Bacterial flagella aid in locomotion and attachment and are therefore critical virulence 
factors (Mobley et al., 1996). Attached to a molecular motor, each flagellar filament is made of 
eleven protofilaments, comprised of flagellin monomers termed FliC, that have four domains 
(D0, D1, D2, and D3) (Figure 2, Yonekura et al., 2003). The crystallized hairpin structure of each 
monomer reveals these domains to be discontinuous (Namba et al., 1989), so that the linear 
structure is: N terminus D0- D1- D2 - D3- D2 - D1- D0 - C terminus.  
 Comprising the D1 domain, the amino- and carboxyl- terminal ends of FliC are highly 
conserved among Salmonella and other Gram-negative bacteria (Namba et al., 1989 and Mimori-
Kiyosue et al., 1998) and are known to interact with TLR5 (Eaves-Pyles et al., 2001; Donnelly 
and Steiner, 2002; Murthy et al., 2004) through three lateral helices (Figure 3, Yoon et al., 
2012).  The D3 domain is neither conserved nor required for TLR5 activation, and is therefore 
referred to the hypervariable region (Lino, 1977).  
1.3 Flagellin as a Biological Adjuvant  
 Because FliC activates innate immunity through TLR5, it can serve as a biological vaccine 
adjuvant when genetically linked to other antigens. Presentation of such heterologous proteins 
could surmount a greater immune response than the singular counterpart. Ruth Arnon and 
colleagues were the first to use flagellin as a biological adjuvant and others have since 
demonstrated its capacity in this role (McEwen et al., 1992; Levi and Arnon, 1996; Ben-Yedidia 
and Arnon, 1998; Ben-Yedidia et al., 1998; 1999a; 1999b). Since then, many other researchers 
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have linked the TLR5 activator to known antigens (Table 2), establishing it as an effective 
vaccine adjuvant.  
 
 
 
Figure 2: Full Length Flagellin Protein Structure 
Flagellin is comprised of four structural domains that aid in protein folding and TLR5 recognition. 
Kaisho, T. and S. Akira. 2002. Toll-like receptors as adjuvant receptors. Biochim. Biophys. Acta. 1589: 1-13. 
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Figure 3: FliC interacts with TLR5 
The D1 domain contains three highly conserved helices required for TLR5 activation. 
Yoon, S., O. Kurnasov, V. Natarajan, M. Hong, A.V. Gudkov, A.L. Osterman, and A.I.Wilson. 2012. 
Structural basis of TLR5-flagellin recognition and signaling. Science 335: 859-864. 
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Table 2: Recombinant Flagellin Vaccines 
 
Recombinant Flagellin Vaccine Reference 
Flagellin – Influenza hemagglutinin epitopes McEwen et al., 1992 
Levi and Arnon, 1996 
Ben-Yedidia and Arnon, 1998 
Ben-Yedidia et al., 1998 
Ben-Yedidia et al., 1999a 
Jeon et al., 2002 
Adar et al., 2009 
 
Flagellin – Influenza hemagglutinin globular head domain Song et al., 2009 
Flagellin – Influenza virus M2e ectodomain Huleatt et al., 2008 
Flagellin – Schistosoma mansoni epitope Ben-Yedidia et al., 1999b 
Flagellin – Campylobacter coli maltose-binding protein Lee et al., 1999 
Flagellin – Escherichia coli colonization factor I epitope das Graças Luna et al., 2000 
McSorley et al., 2000 
Strindelius et al., 2004 
Flagellin – Escherichia coli heat-stable toxin Pereira et al., 2001 
Flagellin – Tetanus toxoid Lee et al., 2006 
Flagellin – West Nile virus envelope protein McDonald et al., 2007 
Flagellin – Plasmodium antigen Bargieri et al., 2008 
Bargieri et al., 2010 
Leal et al., 2013 
Flagellin – Yersinia pestis F1 antigen Honko et al., 2006 
Flagellin – Vaccinia virus L1R and B5R antigens Delaney et al., 2010 
Flagellin – Helicobacter pylori antigen Mori et al., 2012 
Flagellin – Pseudomonas aeruginosa OprF epitope Weimer et al., 2009a 
Weimer et al., 2009b  
 
1.4 First Generation FliC:Antigen Fusion Protein 
 Previous research within this lab linked native Salmonella FliC (Figure 4, Genbank 
Acquisition: D13689) with antigens like those for Marberg and influenza.   
  
Figure 
5’ – 3’ DNA coding 
  
 This approach utilized naturally o
throughout the fliC sequence but had several pi
steps during the cloning and expression processes.  First, 
proposed antigens must be extensively analyzed f
recognition sites.  If the antigen were
only be located once in both sequences
times, PCR must be utilized to construct a sequence without the site while maintaining the same 
amino acid sequence.  Redundancy of the genetic code 
substitutions to yield the same protein sequence as that containing an unwanted restriction 
enzyme recognition site.   
 
 
4: Full length flagellin 5' - 3' DNA sequence 
sequence of Salmonella flagellin. GenBank Acquisition: D13689
ccurring, blunt-ended restriction enzyme recognition sites 
tfalls that required unnecessarily complicated 
the DNA sequences of both 
or the presence of unwanted restriction enzyme 
 to be linked to FliC using the FatI enzyme, that site should 
 to avoid an unwanted digest.  If the site exists multiple 
(Figure 5) allows single nucleotide 
 
8
 
 
flic and the 
  
There are 64 codons that code for only 20 amino acids.
Image Source: http://patentimages.storage.googleapis.com/WO2005021588A1/imgf000009_0001.png
 
 For example, the DNA sequence 5’
Threonine-Asparagine-Serine but also contain
5’ GAATTC 3’. To remove this unwanted site, one base must be substituted that would maintain 
the aforementioned protein sequence. 
maintains the polypeptide but lacks the EcoRI site.  While this oversim
corrected, removing an unwanted restriction enzyme recognition site 
intensive, especially if the unwanted site is located within
the use of overlapping PCR (Figure 6
 
 
 
Figure 5: The Genetic Code 
 
 ACG-AAT-TCC 3’ codes for the peptide sequence 
s the EcoRI restriction recognition site
 The corrected DNA sequence 5’ ACA-AAT
plified example is easily 
is very time 
 the middle portion of a 
).   
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,  
-TCC 3’ 
and labor 
gene, requiring 
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Figure 6: Overlapping PCR 
Overlapping PCR can be used to remove unwanted restriction enzyme recognition sites. Primers are used to  
introduce a needed mutation and to create a final fragment without the site.  
Image adapted from: http://upload.wikimedia.org/wikipedia/commons/8/8b/Overlap_Extension_PCR.png 
 
 Secondly, it is commonly known that the use of blunt-ended restriction enzymes leads to 
low ligation efficiency and transformation yield. It would be optimal to utilize enzymes that 
leave “sticky ends,” ensuring greater recombination success with proper orientation.  Lastly, 
utilizing the native fliC sequence requires separate cloning strategies for each antigen of interest, 
increasing overall time and the variety of needed enzymes.  For these reasons, a more robust and 
customizable FliC was desired to serve as reusable platform for the integration and co-expression 
of many different antigenic proteins. 
Unwanted RE Site
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2 MATERIALS AND METHODS 
2.1 In silico Construct Design  
The native DNA sequence of Salmonella typhimurium phase 1 flagellin (Figure 4) was 
divided into each of its 7 subdomains by manually counting nucleotides (Figure 7). The 
subdomains were then translated using the ExPASy online translator tool found at 
http://web.expasy.org/translate/ (Figure 8) and BLASTED 
(http://www.ncbi.nlm.nih.gov/BLAST/Blast.cgi?PAGE=Proteins) against the native sequence 
for confirmation.  
 
Figure 7: 5’ 3’ Native Salmonella FliC Domains - Color Coded 
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Figure 8: Amino Acid Sequences of Each FliC Domain 
 
  
 The D1 and D2 domains on both termini, responsible for immune system 
recognition, were screened for the absence of all commercially-available restriction 
enzyme sites by using the New England BioLabs Cutter located at 
http://tools.neb.com/NEBcutter2/index.php and choosing the “0 cutters” option. These 
resulting restriction enzymes were manually screened to remove those that leave blunt 
ends, resulting in a list of restriction enzymes that do not cut within the sequence but will 
leave sticky ends after cleavage. This list was further shortened to include only those 
restriction enzymes that recognize multiples of 3 DNA nucleotides, aiding in frame 
maintenance for future cloning (Figure 9).  
 
 
DOMAIN AMINO ACID SEQUENCE 
D0 (N) Met A Q V I N T N S L S L L T Q N N L N K S Q S A L G T A I E R L 
S S G L R I N S A K D D 
D1 (N) A A G Q A I A N R F T A N I K G L T Q A S R N A N D G I S I A Q T 
T E G A L N E I N N N L Q R V R E L A V Q S A N S T N S Q S D L D 
S I Q A E I T Q R L N E I D R V S G Q T Q F N G V K V L A Q D N T 
L T I Q V G A N D G E T I D I D L K Q I N S Q T L G L D T L N V Q 
Q 
D2 (N) K Y K V S D T A A T V T G 
D3 Y A D T T I A L D N S T F K A S A T G L G G T D Q K I D G D L K F 
D D T T G K Y Y A K V T V T G G T G K D G Y Y E V S V D K T N G 
E V T L A G G A T S P L T G G L P A T A T E D V K N V Q V 
D2 (C) A N A D L T E A K A A L T A A G V T G T A S V V K Met S Y T D N 
N G K T I D G G L A V K V G D D Y Y S A T Q N K D G S I S I N T T 
K Y T A D D G T S K T A L N K L G G A D G K T E V V S I G G K T 
Y A A S K A E G H N F K A Q P D L A E A A A T T T E   
D1 (C) N P L Q K I D A A L A Q V D T L R S D L G A V Q N R F N S A I T N 
L G N T V N N L T S A R S R I E 
D0 (C) D S D Y A T E V S N Met S R A Q I L Q Q A G T S V L A Q A N Q V 
P Q N V L S L L R Stop 
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Figure 9: Possible Restriction Enzymes to be Used in the FliC Construct 
 
 
To aid in ligation into commercially available expression vectors, the most commonly 
used restriction enzymes were incorporated on the 5’ and 3’ ends, flanking the D2 domains. The 
length of D3 domain/hypervariable region was maintained, although the DNA sequence was 
altered so that one of the restriction enzyme recognition sites (Figure 9) was incorporated 
between every 15 native nucleotides (Figure 18).  
 
2.2 Construct Synthesis 
 The following 5’-3’ sequence of the Synthetic FliC Expression Platform (Figure 10) was 
  
optimized for expression in E. coli
the pJ404 expression vector for a total recomb
Figure 10: Original 
Original 5’ – 3’ DNA sequence 
 
Figure 11: Final 5'
5’-3’ DNA s
 
 
 (Figure 11) and synthesized by DNA2.0 (Menlo Park, CA) in 
inant length of 4140 base pairs: 
5'-3' DNA sequence of FliC Expression Platform
submitted to DNA2.0, before optimization for expression in 
 
-3' DNA Sequence of FliC Expression Platform
equence after codon optimization for expression in E. coli
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E. coli 
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2.3 Transformation of BL21 E. coli Expression Strain 
One tube of BL21 competent E. coli cells (New England Biolabs, C2530) was thawed on 
ice for 10 minutes and mixed with 100ng of reconstituted pJ404 plasmid DNA containing the 
FliC construct by gentle pipetting. The mixture was placed on ice for 10 minutes, transferred to a 
42°C water bath for exactly 10 seconds, and placed back on ice for 5 minutes. Cells were 
allowed to recover for 60 minutes in 950µL Super Optimal broth with Catabolite repression 
(SOC) medium (2% w/v Tryptone, 0.5% w/v Yeast Extract, 10mM NaCl, 2.5mM KCl, 10mM 
MgCl2, 20mM Glucose) shaking at 200rpm at 37°C.  Meanwhile, Luria Bertani (LB) Agar 
selection plates containing 100µg/mL ampicillin were warmed to 37°C. 100µL of transformed 
cells and 100µL of each of three serial dilutions (10-1, 10-2, 10-3) were used to inoculate 4 
separate warmed plates. The plates were allowed to sit upright on the bench top for one hour and 
then incubated upside down at 37°C overnight.  
2.4 Culture Maintenance  
2.4.1 LB Glycerol Stocks 
One resulting colony was picked from the undiluted sample and transferred to a 50mL 
falcon tube containing 20mL LB broth with 100µg/mL ampicillin and allowed to grow at 37°C, 
shaking at 200rpm overnight. 0.5mL of the overnight culture was added to 0.5mL filter-sterilized 
60% glycerol, to achieve a 30% glycerol stock, and stored at -80°C. 
2.4.2 Adaptation to Fermentation Media  
100mL of E. coli Adaptation Media [(ECAM) per liter: 7.8g KH2PO4, 1.0g Citric Acid, 
2.33g (NH4)2SO4, 1mL Trace Metal Solution, 1mL Thiamine HCl Solution, 40mL Glucose Stock 
Solution, 13mL MgSO4 Solution, 0.5mL CaCl2 Solution; Trace Metal Solution: 900mL warm 
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ddH2O, 5g EDTA, 10g FeSO4.7H2O, 2g ZnSO4.7H2O, 2g MnSO4.H2O, 0.2g CoCl2.6H2O, 0.1g 
CuSO4.5H2O, 0.2g NaMoO4.2H2O, 0.1g H3BO3, dissolved and brought up to 1L with ddH2O, 
autoclaved at 121°C for 30 minutes; Thiamine HCl Stock: 950mL ddH2O, 10g Thiamine HCl, 
dissolved and made up to 1L with ddH2O and filter sterilized; Glucose Stock Solution: 700mL 
ddH2O, 250g glucose, dissolved and made up to 1L with ddH2O and filter sterilized; MgSO4 
Stock Solution: 900mL ddH2O, 78g MgSO4, dissolved and made up to 1L with ddH2O and filter 
sterilized; CaCl2 Stock: 950mL ddH2O, 80g CaCl2, dissolved and made up to 1L with ddH2O and 
filter sterilized]  containing 100µg/mL ampicillin was warmed to 37°C and inoculated with a 
1mL glycerol stock of the BL21 E. coli containing the recombinant pJ404 plasmid in a sterile 
250mL flask. The culture was allowed to grow overnight at 37°C, shaking at 200rpm. The 
following day, the OD600 was measured and the volume needed to yield an OD600 of 0.05 was 
used to inoculate a 250mL flask containing 100mL ECAM with 100µg/mL ampicillin. Once an 
OD600 of 0.8-1.2 was achieved, 0.5mL of the culture was added to 0.5mL filter-sterilized 60% 
glycerol to achieve a 30% glycerol stock and stored at -80°C as ECAM-adapted cells. 
2.5 Induction Analysis 
2.5.1 Cytotoxicity Assay 
A 1.0mL 30% glycerol stock of either BL21 housing recombinant pJ404 or BL21 with no 
plasmid was used to inoculate two 50 mL falcon tubes containing 20mL LB broth with and 
without 100µg/mL ampicillin, respectively. The cultures were incubated overnight at 37°C 
shaking at 200rpm.  A volume of these cultures was used to inoculate the following experimental 
samples to an initial OD600 of 0.1 in 10mL LB broth plus antibiotics where appropriate in 15mL 
falcon tubes: BL21 with no plasmid, Uninduced BL21 with recombinant pJ404, and Induced 
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BL21 with recombinant pJ404. 1mM IPTG was added to the Induced culture once the OD600 
reached 0.2. The cultures were allowed to grow for 300 minutes, shaking at 200RPM at 37°C, 
and triplicate samples were taken every 30 minutes to measure the OD600.  
2.5.2 Flask work  
20mL of LB, 100mL of ECAM, and 100mL of Partially Defined E. coli Adaptation 
Media [(PECAM) per liter: 10g Yeast Extract, 20g Tryptone, 3g KH2PO4, 6g K2HPO4, 2g 
(NH4)2SO4, 1mL Trace Metal Solution, 0.02g Thiamine HCl, 20g Glucose, 1g MgSO4.7H20, 
0.5mL CaCl2 Solution] each containing 100µg/mL ampicillin, were warmed to 37°C and 
inoculated with a 1mL glycerol stock of the adapted BL21 E. coli containing the recombinant 
pJ404 plasmid. The culture was allowed to grow overnight at 37°C, shaking at 200rpm. The 
following day, the OD600 was measured and the volume needed to yield an OD600 of 0.05 was 
used to inoculate 2, 250mL flasks with 100mL of each media containing 100µg/mL ampicillin. 
Once an OD600 of 0.8-1.2 was achieved, an 80mM IPTG stock solution was added to one culture 
to yield a final concentration of 1mM IPTG and the other culture served as the uninduced 
control.  After three hours of growth at 37°C, shaking at 200rpm, 10mL samples were taken from 
each culture and placed in 15mL falcon tubes and stored for up to 8 hours at 4°C.  
2.6 Fermentation with ECAM and PECAM 
2.6.1 Inoculum preparation: ECAM 
A 1mL adapted glycerol stock stored at -80°C was used to inoculate 250mL ECAM with 
100µg/mL ampicillin in a sterile1L flask. The culture was incubated at 37°C while shaking at 
200rpms for 14.5 hours.  After, 2.8mL of the culture was transferred to 250mL ECAM with 
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100µg/mL in a 1L flask to yield a starting OD600 of 0.1. After 6 hours the OD600 was 1.5 and 
80mL of this culture was used to inoculate the vessel to a starting OD600 of 0.012.  
2.6.2 Inoculum preparation: PECAM 
250µL of a 1mL adapted glycerol stock stored at -80°C was used to inoculate 250mL 
ECAM with 100µg/mL ampicillin in a sterile1L flask. The culture was incubated at 37°C while 
shaking at 200rpms for 16 hours.  After, 2.5mL of the culture was transferred to 250mL PECAM 
with 100µg/mL in a 1L flask to yield a starting OD600 of 0.1. After 5 hours the OD600 was 5.0 
and 20mL of this culture was used to inoculate the vessel to a starting OD600 of 0.012.  
2.6.3 Vessel Set Up/ Fermentation Run: ECAM 
 The Biostat C 20L vessel was autoclaved with 2.5L of ddH2O and 1.5L of 10X EBAT 
(750µL Antifoam, 22g KH2PO4, 10g Citric Acid, 45g (NH4)2SO4,10mL Trace Metal Solution, 
10mL Thiamine HCl Solution) and 2L of 10X EBAT II (875mL Glucose Stock Solution, 130mL 
MgSO4 Solution, 5mL CaCl2 Solution, 100mg/L ampicillin, dissolved and brought up to 2L with 
ddH2O and filter sterilized) was added. After inoculation, a 10mL sample was taken and a 
loopful was transferred to both a Nutrient Agar (NA) plate and a LB agar plate with 100µg/mL 
ampicillin and incubated at 37°C to check for contamination and insure plasmid integrity, 
respectively.  The glucose concentration was 16.8g/L and the ampicillin concentration was 
100mg/L. 
The temperature was set at 30°C and the pH was maintained at 7.0.  Dissolved oxygen 
was maintained at 30% by cascade control with agitation, with a minimum value of 150rpm and 
a maximum of 450rpm, and gas mix.  Airflow was maintained 10 LPM.  
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2.6.4 Vessel Set Up/ Fermentation Run: PECAM  
The Biostat C 20L vessel was autoclaved with 8.5L of double deionized water and 1.5L 
of 10X PEBAT (10X PECAM with 750µL antifoam) was added. After inoculation, a 10mL 
sample was taken and a loopful was transferred to both a Nutrient Agar (NA) plate and a LB agar 
plate with 100µg/mL ampicillin and incubated at 37°C to check for contamination and insure 
plasmid integrity, respectively.  The glucose concentration was 19.6g/L and the ampicillin 
concentration was 100mg/L.  
The temperature was set at 30°C and the pH was maintained at 7.0.  Dissolved oxygen 
was maintained at 30% by cascade control with agitation, with a minimum value of 150rpm and 
a maximum of 450rpm, and gas mix.  Airflow was maintained 10 LPM.  
2.6.5 Induction with 1mM IPTG   
Upon glucose depletion as determined by the YSI, the feed rate was increased to confirm 
0% net glucose accumulation.  A 10mL, uninduced sample was taken and a filter-sterilized IPTG 
solution was injected into the bioreactor to achieve a final concentration of 1mM. During the 
ECAM fermentation, 10mL samples were taken at 1, 2, 3, 4,5, and 22 hours post induction for 
analysis. During the PECAM fermentation, samples were taken at 1, 2, and 3 hours post 
induction for analysis.  
2.7 Preparation of Soluble, Insoluble, and Conditioned Media of Uninduced and Induced     
Samples  
 3mL of each flask sample and 1mL of each fermentation sample were centrifuged at 
14krpm for 5 minutes. The supernatant was removed as “Conditioned Media” and the pellet was 
resuspended in 850µL Phosphate Buffered Saline (137mM NaCl, 12mM Phosphate, 2.7mM 
KCl, pH 7.4) and sonicated on ice 3 times for 10 seconds (1 second on / 0.5 second off).  The 
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sonicated samples were spun at 14krpm for 15 minutes.  The resulting supernatant was removed 
as “Soluble Protein” and the pellet was resuspended in 850µL 50mM Tris, 8M Urea, pH 8.0 as 
“Insoluble Protein.”  
2.8 Sodium Dodecyl Sulfate PolyAcrylamide Gel Electrophoresis (SDS-PAGE) 
 10µL of 4x NuPAGE loading buffer (Novex) was added to 30µL of each sample, 
vortexed, and heated at 80°C for 5 minutes. The samples were centrifuged at 14krpm for 5 
minutes.  10µL of each sample was loaded into each well of a NuPAGE 4-12% Bis-Tris Gel 
(Novex).  The gel was run at 200 volts for 60 minutes in 1X MOPS SDS running buffer (Novex) 
stained overnight in Coommassie Brilliant Blue, and destained in ddH20.  The gel was imaged 
using a Typhoon 9400 scanner (Amersham Biosciences) and Image Quant TL software (General 
Electric).  
2.9 Western Blot 
The proteins separated by SDS-PAGE were transferred onto a nitrocellulose membrane 
(Invitrogen, LC2000) for 1 hour at 30 volts.  Gel-to-membrane contact was maintained 
throughout by pressure from blotting pads and filter paper soaked in 1X Transfer Buffer [50mL 
20X NuPAGE Transfer Buffer (Novex NP0006), 100mL methanol, 850mL ddiH20], sandwiched 
within the Blot Module filled with 1X Transfer Buffer.  
After, non-specific binding sites were blocked by incubating the membrane in 5% nonfat 
milk in 1X TBST [100mL 10X TBS (0.2M Trizma-HCl, 1.5M NaCl, pH 7.6), 900mL ddH20, 
1mL Tween-80], overnight shaking at 60rpm at 4°C. The membrane was washed 3 times for 5 
minutes with 1X TBST shaking at 100rpm at 4°C, followed by an hour incubation shaking at 
100rpm at 4°C with the Mouse Anti-Flagellin Primary Antibody (InvivoGen) diluted to 1:1000 
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in 1X TBST. The membrane was then washed once with 1X TBST for 15 minutes, shaking at 
100rpm at 4°C, followed by four more washes for 5 minutes, shaking at 100rpm at 4°C. The 
membrane was then incubated for one hour, shaking at 100rpm at 4°C, with the Goat Anti-
Mouse Antibody (Invitrogen, 62-6720), diluted to 1:10,000 in 1X TBST. The membrane was 
then washed once with 1X TBST for 15 minutes, shaking at 100rpm at 4°C, followed by four 
more washes for 5 minutes, shaking at 100rpm at 4°C. 
The membrane was incubated with Chemiluminescence Reagent (PerkinElmer, 
NEL103001EA) according to the manufacturer’s protocol and imaged using the  
ImageQuant4000 (General Electric).  
2.10 Protein Analysis via MALDI MS/MS 
Bands of interest were excised from the stained SDS-PAGE gel and placed in 200µL 
ddH20 and submitting to the protein sequencing facility in the Georgia State University Core 
Facility for Matrix Assisted Laser Deabsorption Ionization (MALDI) mass spectrophotometry/ 
mass spectrophotometry (MS/MS) analysis.  
3 RESULTS 
3.1 Cytotoxicity Assay  
Presence of the recombinant pJ404 plasmid in BL21 E. coli cells showed no negative 
impact on growth as compared to that of cells without the plasmid (Figure 12). Also, the addition 
of 1mM IPTG for protein induction at approximately 30 minutes post-inoculation also did not 
negatively impact cell growth.  The optical densities of the induced sample decreased after the 
7th time point (210 minutes post-inoculation), however this slight decline was attributed to 
variability within the shaker.  
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3.2 Flask work: Induction in LB 
SDS-PAGE and Western blot analyses of recombinant BL21 E. coli cells grown in 20mL 
LB broth and induced with 1mM IPTG demonstrated target protein expression primarily in the 
insoluble fractions (IP) after both 3 and 24 hours of induction (Figure 13). The major band 
located in the insoluble fraction after 24 hours of induction was sequenced in the GSU Core 
Facility using MALDI MS/MS. The resulting sequence matched that of native FliC, correlating 
to 53 and 59 peptides on the N and C termini, respectively. The lower major band (~42kDa) was 
also sequenced and demonstrated homology with OmpF, an outer membrane protein that is seen 
in most of the E. coli protein work conducted in this laboratory. The third major band (~38kDa) 
could be the result of degradation or truncation, cleavage, or an aggregation of proteins that 
migrate more rapidly than their fully denatured counterparts. The faint band seen around 55kDa 
could be attributed to dimerization of the synthetic FliC protein.  
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Figure 12:  Effects of Plasmid and Induction on BL21 Cell Growth.  
Cells were grown in LB Broth supplemented with 100µg/mL ampicillin at 37°C shaking at 200rpm for 300 minutes.  
Triplicate samples were taken every 30 minutes and the OD600 values were measured and averaged. 
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Figure 13: Induction in LB: Flask work.  
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3.3 Flask work: Induction in ECAM 
After growth and induction in 100mL ECAM, SDS-PAGE analysis demonstrated a major 
band in the insoluble fraction, a minor band in the soluble fraction, and a faint band in the 
conditioned media (Figure 14). Western blot analysis confirmed strong expression within the 
insoluble fraction after only 3 hours of induction with 1mM IPTG. The small, 38kDa protein 
produced after growth in ECAM (Figure 14) and in LB (Figure 13) could be the product of 
protein degradation, cleavage, or aggregation 
3.4 Flask work: Induction in PECAM 
Growth and induction in PECAM followed by SDS-PAGE and Western blot analyses of 
cellular fragments resulted in a major protein band at approximately 45kDA, primarily in the 
induced insoluble and soluble fractions, indicating strong induction of the FliC construct (Figure 
15). As seen in Figures 13 and 14, growth in PECAM also produced a 38kDa protein, indicating 
possible protein degradation or clumping.   
3.5 Fermentation in ECAM  
After a 20-liter fermentation in ECAM involving 22 hours of induction, the expected 
45kDa protein was only present in the conditioned media after SDS-PAGE and Western blot 
analysis (Figure 16). Full-length product was seen neither in the soluble nor insoluble fractions, 
even after 22 hours of induction. However, a smaller band around 28kDa was confirmed in the 
Western blot to be part of FliC and displayed a strong banding pattern in the insoluble fractions.  
This sized fragment was not created in the LB (Figure 13), ECAM (Figure 14), or PECAM 
(Figure 15) flask work.  Also of note, the band commonly seen at 38kDA was only present in the 
conditioned media. 
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3.6 Fermentation in PECAM 
A 20-liter fermentation in PECAM demonstrated target protein expression after 1,2, and 
3 hours of induction with 1mM IPTG compared to the uninduced control, as seen in the SDS-
PAGE and Western blot in Figure 17. The ~38kDA protein present in the ECAM (Figure 14) and 
PECAM (Figure 15) flask work but absent in the soluble and insoluble fractions of the ECAM 
fermentation samples (Figure 16) was primarily expressed in the insoluble fractions after 
fermentation using PECAM (Figure 17).  To add, the 28kDA protein in the soluble and insoluble 
fractions of the ECAM fermentation samples (Figure 16) was absent from the PECAM 
fermentation samples (Figure 17).
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Figure 14: Induction in ECAM: Flask Work.  
SDS-PAGE and Western Blot of protein samples extracted from BL21 with the 
recombinant plasmid grown in ECAM at 37°C shaking at 200rpm, uninduced and induced with 1mM IPTG for 3 hours. 
CM: Conditioned Media, SP: Soluble Protein, IP: Insoluble Protein
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Figure 15: Induction in PECAM: Flask Work 
 SDS-PAGE and Western Blot of protein samples extracted from BL21 with the 
recombinant plasmid grown in PECAM at 37°C shaking at 200rpm, uninduced and induced with 1mM IPTG for 3 hours. 
CM: Conditioned Media, SP: Soluble Protein, IP: Insoluble Protein
SDS-PAGE 
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Figure 16: ECAM Fermentation. 
SDS-PAGE and Western Blot of protein samples extracted from BL21 with the 
recombinant plasmid grown in 20 Liter ECAM Fermentation at 30°C and induced with 1mM IPTG 
U: Uninduced 1,2,3,4,5,22 – Hours post induction 
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Figure 17: PECAM FERMENTATION.  
SDS-PAGE and Western Blot of protein samples extracted from BL21 with the 
recombinant plasmid grown in 20 Liter PECAM Fermentation at 30°C and induced with 1mM IPTG 
CM: Conditioned Media SP: Soluble Protein IP: Insoluble Protein 
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4 DISCUSSION 
4.1 Second Generation FliC-Antigen Co-Expression Platform 
 To effectively use FliC as a platform technology for the production of biological vaccine 
adjuvants, a construct was created that allows antigenic proteins to be placed at the N-terminus, 
C-terminus, and within the hypervariable region (Figure 18).  The N-terminal and C-terminal D0 
domains were replaced with commonly used restriction enzyme recognition sequences, as these 
native sequences have not been demonstrated necessary for TLR5 activation, and the 
hypervariable region was replaced with a synthetic sequence of restriction enzyme recognition 
sites between every fifteen native nucleotides. 
4.1.1 Rationale For N and C Terminal Sequences 
 Eaves-Pyles and colleagues (2001) were the first to study the effects of FliC mutations on 
immune response and begin pinpointing the sequences necessary for inflammation.  They created 
a series of FliC protein-fraction fusions and tested for bioactivity, determining that the most 
conserved amino and carboxyl termini are required for an immune response.  In 2002, Donnelly 
and Steiner worked to further isolate the FliC amino acids required for an inflammatory response 
by creating a series of deletion and insertion mutants and measuring subsequent Interleukin (IL)-
8 release. They concluded that the last 121 residues of the N-terminal D1 and the first 12 residues 
in D2 are required for inflammation. One year later Smith et al. also constructed a variety of FliC 
mutants and determined that a deletion of the first 100 amino acids in the N-terminal D1 domain 
resulted in complete loss of TLR5 activation and removing amino acids 416-444 in the C 
terminus caused the same effect. In studying the mechanism by which some flagellated bacteria 
circumvent the immune system, Andersen-Neissen and colleagues (2005) discovered that amino 
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acids 89-96 within the N terminus are required for TLR5 activation. In 2012, Yoon et al. 
continued this research by resolving the crystal structure of Zebrafish TLR5 complexed with 
Salmonella FliC. It was determined that only the D1 domain interacts with the receptor. 
Combining these data, removing the D0 domain should have no effect on TLR5 activation as 
long as the D1 and D2 domains remain intact, and therefore the second generation FliC-Antigen 
Co-expression platform contains popular restriction enzyme recognition sites at this location.  
4.1.2 Rationale For Hypervariable Region Sequence 
Eaves-Pyles et al. (2001) created a flagellin mutant containing the native N and C 
terminal conserved domains and replaced the hypervariable region with an unrelated E. coli 
DNA sequence and found this mutant to stimulate innate immunity like wild type flagellin. They 
then speculated that the D3 domain allows the D1 and D2 domains to interact and activate TLR5.  
Donnelly and Steiner (2002) confirmed that a large deletion within this region had no effect on 
inflammation but an insertion led to decreased inflammation. This insertion might have a 
consequence on the spatial relationship between the D1 and D2 domains, causing diminished 
TLR5 activation. Liu et al. (2010) set out to definitively identify the role of the hypervariable 
domain in innate immunity and adjuvancy by creating three distinct deletion mutants: ∆190-278, 
∆220-320, ∆180-400, all of which lost their antigenicity. Based on these results combined, the 
length of the D3 domain is required for proper protein folding and subsequent TLR5 activation 
but the sequence is irrelevant.  Therefore, the hypervariable domain of the synthetic FliC 
construct is the same length as that of native flic but contains a 6 base pair restriction enzyme 
recognition sequence every 15 nucleotides, allowing antigens of a variety of lengths to be 
inserted into this region.  
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Figure 18: Synthetic FliC Expression Platform 
D0 and D3 domains were replaced with commonly used restriction enzyme recognition sites while D1 and 
D2 remain for proper TLR5 activation.  
 
 
4.2 Production in BL21 E. coli via pJ404 
4.2.1 Synthesis in pJ404   
   The FliC-Antigen co-expression platform is capable of stable integration within a 
variety of expression vectors, given that the most commonly used restriction enzymes are 
located on the 5’ and 3’ ends of the platform DNA sequence.  For initial synthesis, DNA2.0 
provided an inducible expression vector, pJ404, which utilizes an IP-free T5 promoter.  This 
conscious choice to move away from the traditionally used T7 promoter safeguards the future 
patentability of the construct, should the Brookhaven National Laboratory, under contract with 
the U.S. Department of Energy, decide to patent and require licensure for the production of 
transcripts utilizing the T7 promoter (Studier, 2005). The T5 promoter system was first 
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described in 1985 by Gentz and Bujard, and has since been used and modified by many 
companies.  DNA2.0 has not patented their changes to the T5 promoter system and insures their 
gene constructs are IP-free. The recombinant pJ404 was transformed into chemically competent 
BL21 E. coli cells via heat shock. The BL21 strain is suitable for the expression of all non-T7 
transcripts and is deficient of both Lon and OmpT proteases.  Such strains are very useful for 
the expression of recombinant proteins because the otherwise present proteases would cleave 
misfolded and exogenous proteins, respectively.  
4.2.2 Induction in LB 
When BL21 cells transformed with pJ404 containing the synthetic FliC construct were 
grown in LB broth and induced with 1mM IPTG, expression of the construct was seen primarily 
in the insoluble fractions (Figure 13).  This protein sequence was confirmed through MALDI 
MS/MS and was used as an indicator band for all future induction studies.  Although the amount 
of protein loaded in each lane of the gel in Figure 13 is not exactly the same, each processed 
pellet was resuspended in the same volume of buffer and therefore expression levels can be 
compared across samples with some level of certainty.  In this way, there was no apparent 
increase in synthetic FliC production after 24 hours of induction, as compared to 3 hours of 
induction.  Also, there was no major shift in protein expression between the soluble to insoluble 
fractions over time, as is often the case when proteins begin to form inclusion bodies and 
aggregate.  
To add, the synthetic FliC construct was either cleaved or formed fragments, as seen at 
the 38kDA band on the SDS-PAGE and confirmed by interaction with the anti-FliC primary 
antibody in the Western blot (Figure 13). This smaller version of the construct was present in all 
three protein fractions but was most apparent in the insoluble fractions of both uninduced and 
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induced samples. Although it is unclear why the cell would process the protein in this way, it is 
plausible that the E. coli is truncating the monomer in an effort to form a functional flagellum.  
4.2.3 Induction in ECAM 
Because traditional media like LB is insufficient at maintaining high cell densities 
common to large-scale production, a defined media containing ample amounts of glucose and 
transcriptional cofactors was used for cell adaptation and fermentation. After two passes in 
ECAM, the cells were glycerol stocked and used as inoculum for flask work and 20 liter 
fermentations.  
In the flask, recombinant cells grown in ECAM and induced with 1mM IPTG express the 
synthetic FliC protein primarily in the insoluble fraction, but it is also seen in the conditioned 
media and soluble fractions after 3 hours of induction (Figure 14). Interestingly, growth in 
ECAM also promotes the formation of the 38kDA FliC fraction, similar to that produced in LB. 
In ECAM, however, there is difference in expression levels between the uninduced and induced 
samples that was not noted in the LB samples.  
Using ECAM for a 20 liter fermentation, BL21 cells induced to express synthetic FliC 
demonstrated production only in the conditioned media and this was confirmed through Western 
blot (Figure 16).  The 38kDA fragment noted in both LB (Figure 13) and ECAM (Figure 14) 
flask work also only appeared in the conditioned media.  To add, a new fragment around 28kDa 
was produced primarily in the insoluble fractions but was also seen in the soluble samples.  The 
presence of a smaller protein could indicate that the cell is cleaving the FliC or that processing 
conditions did not inactivate all proteases.  
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4.2.4 Induction in PECAM  
To promote the induction of full-length flagellin, the ECAM media was supplemented 
with defined and scalable amounts of tryptone and yeast extract, according to Tabandeh et al. 
(2004). The additional tryptone serves as a source of amino acids, promoting expression of 
recombinant proteins. As seen in Figure 15, the 45kDa protein of interest was induced and 
expressed in all three fractions after only 3 hours of induction in the flask, as compared to the 
uninduced control. The 38kDa truncated FliC was also present in all three fractions but was 
primarily produced in the soluble and insoluble fractions after induction.  
Using PECAM in a 20 liter fermentation, full length synthetic FliC was produced in the 
insoluble fractions after 1, 2 and 3 hours of induction (Figure 17).  To add, the 38kDa, truncated 
version was also present in the insoluble fractions but the smaller 28kDa fragment produced 
during the ECAM fermentation was not.  To promote the production of full length synthetic 
FliC, and inhibit any truncated forms, PECAM serves as a viable candidate for future 
fermentation experiments to optimize the concentration of IPTG, temperature, and oxygen levels.  
4.3 Utilizing Other Expression Vectors and Hosts    
4.3.1 pET Blue Vectors  
 If expression in a different vector or host is required for future applications, the 
synthetic FliC construct can readily be cloned into the pETBlue-2 plasmid for expression in other 
strains of E. coli (Novagen, Figure 19). Utilizing the 5’ restriction enzyme site NcoI and the 3’ 
site NotI, the construct can be ligated into the multiple cloning site of pETBlue-2.  The NcoI site 
is unique in that it also contains the start codon ATG, initiating transcription and translation of 
any downstream DNA sequence.  
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Figure 19: pETBlue-2 
pETBlue-2  vector for expression in E. coli (Novagen) 
 
 
 
 This system utilizes two cell types: one for cloning and one for expression.  The NovaBlue 
cloning host provides a quick blue/white screen for insertion within the multiple cloning site.  
This cell type contains a lacZ ω-fragment that is complemented by the plasmid’s lacZ α-
fragment, producing a functional β-galactosidase that can degrade X-gal to produce a blue 
colony. When the multiple cloning site is disrupted, the α-fragment is not produced and the cells 
are rendered white.  This quick screen circumvents the need for colony PCR, removing an extra 
day from the total process time. After successful digest and ligation, white clones are further 
confirmed through PCR and sequencing, and the pETBlue-2 plasmid is extracted and then 
transformed into the DE3(tuner)pLacI E. coli expression host.  Basal levels of protein expression 
are kept to a minimum in this cell type through the use of a chromosomal T7 RNA Polymerase 
that is under control of the lacUV5 promoter and subsequently repressed by the addition of 1% 
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glucose in the media. IPTG can then be used to induce expression of genes placed within the 
multiple cloning site.  
4.3.2 Production in a Eukaryotic Host 
In addition to E. coli, this platform can also be successfully produced and secreted by 
Pichia pastoris through the use of the pGAPZα-B plasmid (Invitrogen, Figure19). This B-type 
plasmid is one within a set of three (A, B, and C) for cloning in frame with an N-terminal α-
secretion factor from Saccharomyces cerevisiae that is cleaved by the expression host.  
This vector is industrially optimized for the constitutive expression of recombinant 
proteins through stable integration within the glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) promoter.  Because this gene is a critical part of the glycolysis pathway, it is always 
transcribed and translated.  Therefore, transgenic proteins located within the GAPDH promoter 
will also be constitutively expressed. The pGAPZα-B plasmid contains a region of homology for 
crossover and subsequent expression of the gene of interest, Zeocin antibiotic resistance, and 
GAPDH. Using this system, initial cloning occurs in E. coli through standard electroporation or 
heat shock and proper ligation is confirmed using PCR.  The recombinant plasmid is then 
linearized and transformed into competent Pichia via homologous recombination.  
4.4 Real World Applications/Relevance of Project 
 Production of a novel, recombinant FliC-Antigen co-expression platform will lead to a 
variety of applications.  First, this synthetic FliC can be used to increase the efficacy of currently 
available vaccines or to increase the immune response of antigens previously found to not be 
efficacious.  Additionally, this construct can be used to simultaneously express several antigens, 
incorporating them into a multivalent vaccine while cutting down on production costs and time.  
For instance, the Diphtheria, Tetanus and Pertussis vaccine (DTaP) is currently given as one 
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injection but is produced in three different hosts.  Using the FliC platform, each antigen can be 
expressed in the same host within the same protein structure to yield a more efficacious vaccine. 
Lastly, using recombinant DNA technologies and producing antigenic proteins in microbial 
systems drastically reduces the time and costs associated with the current egg-based vaccine 
production which could be completely wiped out in the event of pandemic bird flu.  
 
Figure 20:pGAPZ  
pGAPZ vector for expression in Pichia pastoris (Invitrogen) 
 
Work has already begun to incorporate a variety of antigens within this expression 
platform.  Of note, cloning strategies for incorporating antigenic StxB from Shigella 
dysenteriae SD197, Stx2B from E. coli O157:H7, and HagA from Porphyromonas 
gingivalis have been determined.  
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5 CONCLUSION 
5.1 Experimental Conclusions 
The recombinant FliC-antigen co-expression platform has been successfully produced in 
the bioreactor using both ECAM and PECAM. The former yields target protein expression in the 
media, potentially reducing the overall purification processing time, while the latter demonstrates 
expression in the insoluble cellular fraction. Under both conditions, truncated versions of the 
protein were produced that interacted with the anti-FliC antibodies. These smaller fragments 
could be a result of early translation termination or a byproduct of over-induction, and the 
growth variables must be optimized for full-length protein production.  
5.2 Future Work 
The novel, recombinant FliC-antigen co-expression platform will be produced in both E. 
coli and P. pastoris.  The conditions for optimal fermentation and expression induction will be 
determined and the protein will be produced in large quantities. From these preliminary studies, 
it is clear that IPTG concentrations, media components, temperature, induction OD, and oxygen 
levels must be optimized.  These parameters will also need to be adjusted for each subsequent 
antigen co-expressing clone. The resulting cell paste will then be subjected to Akta purification 
using column chromatography to isolate only the FliC protein or Flic-Antigen chimera. This 
purified product will be tested using the TLR5 cell assay to determine its immune response 
efficiency.  If the protein stimulates the immune response at the same level or greater than native 
FliC, work will continue to incorporate other antigenic proteins within the sequence. In addition 
to serving as a vaccine adjuvant, the synthetic FliC protein could potentially be sold as a research 
chemical, once sufficiently purified and proven to active TLR5.  
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